Inhibikase Therapeutics, Inc. (IKT) has a consensus analyst rating of Hold, based on 2 analysts covering the stock. Of those, 0 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for IKT is $4.00, representing a +135.3% upside from the current price of $1.7. Price targets range from a low of $4.00 to a high of $4.00.
